Immune Globulin Subcutaneous (Human), 20% Solution

DRUG3 trials

Sponsors

Baxalta now part of Shire, Takeda, University of Alberta

Conditions

Hypogammaglobulinemia, AcquiredPrimary Immunodeficiency Diseases (PID)

Phase 2

Phase 2/3 Study of IGSC, 20% in PIDD

CompletedNCT01218438

Baxalta now part of ShirePrimary Immunodeficiency Diseases (PID)

Start: 2013-01-28End: 2015-03-13Updated: 2021-07-20

Unknown Phase

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

RecruitingNCT06565078

TakedaPrimary Immunodeficiency Diseases (PID)

Start: 2025-02-17End: 2030-03-31Target: 100Updated: 2026-08-07

Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

RecruitingNCT06989541

University of AlbertaHypogammaglobulinemia, Acquired

Start: 2025-06-01End: 2027-05-01Target: 30Updated: 2025-07-03

Related Papers

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study

Immunotherapy Advances2024-01-011 citations

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.

2023-09-266 citations

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.

2022-08-0710 citations

Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.

2021-10-016 citations

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.

2021-05-263 citations

Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.

2019-06-204 citations